AREC — Arecor Therapeutics Income Statement
0.000.00%
HealthcareSpeculativeSmall CapSucker Stock
- £56.97m
- £48.90m
- £2.40m
Annual income statement for Arecor Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2018 May 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 7 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.35 | 1.1 | 1.7 | 1.16 | 2.4 |
Cost of Revenue | |||||
Gross Profit | 1.35 | 1.1 | 1.7 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.75 | 2.67 | 5.13 | 7.6 | 13 |
Operating Profit | -1.4 | -1.57 | -3.43 | -6.44 | -10.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.43 | -1.57 | -3.51 | -6.95 | -10.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.12 | -1.28 | -2.75 | -6.17 | -9.26 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.12 | -1.28 | -2.75 | -6.17 | -9.26 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.12 | -1.28 | -2.75 | -6.17 | -9.26 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.04 | -0.046 | -0.099 | -0.255 | -0.316 |
Dividends per Share |